Stealth BioTherapeutics Corp (NASDAQ:MITO) – Research analysts at Jefferies Financial Group issued their Q1 2019 earnings per share (EPS) estimates for Stealth BioTherapeutics in a note issued to investors on Tuesday, April 9th, Zacks Investment Research reports. Jefferies Financial Group analyst M. Raycroft expects that the company will earn ($0.26) per share for the quarter. Jefferies Financial Group currently has a “Hold” rating and a $16.00 price target on the stock. Jefferies Financial Group also issued estimates for Stealth BioTherapeutics’ Q2 2019 earnings at ($0.27) EPS, Q3 2019 earnings at ($0.29) EPS, Q4 2019 earnings at ($0.28) EPS, FY2019 earnings at ($1.11) EPS, FY2020 earnings at ($1.08) EPS, FY2021 earnings at ($0.96) EPS and FY2022 earnings at ($0.39) EPS.
Several other research firms also recently issued reports on MITO. Evercore ISI began coverage on Stealth BioTherapeutics in a research report on Tuesday, March 12th. They set an “outperform” rating and a $35.00 target price on the stock. BMO Capital Markets started coverage on Stealth BioTherapeutics in a research report on Tuesday, March 12th. They set an “outperform” rating and a $29.00 target price on the stock. Finally, Nomura started coverage on shares of Stealth BioTherapeutics in a report on Tuesday, March 12th. They issued a “buy” rating and a $23.00 price target on the stock.
About Stealth BioTherapeutics
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.